https://orcid.org/0000-0002-7329-0745
References
- HendersonDJP , HouslayMD , BangmaCH , HoffmannR. Creating a potential diagnostic for prostate cancer risk stratification (InformMDx™) by translating novel scientific discoveries concerning cAMP degrading phosphodiesterase-4D7 (PDE4D7). Clin. Sci.133(2), 269–286 (2019). https://doi.org/10.1042/CS20180519
- MerkleD , HoffmannR. Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: cross-talk with the androgen receptor. Cell. Signal.23(3), 507–515 (2011). https://doi.org/10.1016/j.cellsig.2010.08.017
- BaillieGS. Compartmentalized signalling: spatial regulation of cAMP by the action of compartmentalized phosphodiesterases. FEBS J.276(7), 1790–1799 (2009).
- HendersonDJP , ByrneA , DullaKet al.The cAMP phosphodiesterase-4D7 (PDE4D7) is downregulated in androgen-independent prostate cancer cells and mediates proliferation by compartmentalising cAMP at the plasma membrane of VCaP prostate cancer cells. Br. J. Cancer110(5), 1278–1287 (2014). http://www.nature.com/articles/bjc201422
- Alvesde Inda M , van StrijpD , den Biezen-TimmermansEet al.Validation of Cyclic Adenosine Monophosphate Phosphodiesterase-4D7 for its Independent Contribution to Risk Stratification in a Prostate Cancer Patient Cohort with Longitudinal Biological Outcomes. Eur. Urol. Focus.4(3), 376–384 (2018).
- BöttcherR , DullaK , van StrijpDet al.Human PDE4D isoform composition is deregulated in primary prostate cancer and indicative for disease progression and development of distant metastases. Oncotarget7(43), 70669–70684 (2016). http://www.ncbi.nlm.nih.gov/pubmed/27683107
- BöttcherR , HendersonDJP , DullaKet al.Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression. Br. J. Cancer113(10), 1502–1511 (2015).
- van StrijpD , de WitzC , HeitkötterBet al.The association of the long prostate cancer expressed PDE4D transcripts to poor patient outcome depends on the tumor's TMPRSS2-ERG fusion status. Prostate Cancer.2019 (2019).
- WedgeDC , GundemG , MitchellTet al.Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nat. Genet.50(5), 682–692 (2018). https://doi.org/10.1038/s41588-018-0086-z
- LinB , WhiteJT , FergusonCet al.PART-I: a novel human prostate-specific, androgen-regulated gene that maps to chromosome 5q12. Cancer Res.60(4), 858–863 (2000).
- SidiropoulosM , ChangA , JungK , DiamandisEP. Expression and regulation of prostate androgen regulated transcript-1 (PART-1) and identification of differential expression in prostatic cancer. Br. J. Cancer85(3), 393–397 (2001).
- HuangS , ZouC , TangYet al.miR-582-3p and miR-582-5p Suppress Prostate Cancer Metastasis to Bone by Repressing TGF-β Signaling. Mol. Ther. Nucleic Acids16, 91–104 (2019). http://www.ncbi.nlm.nih.gov/pubmed/30852380
- WangZ , WangY , ZhangJet al.Significance of the TMPRSS2: ERG gene fusion in prostate cancer. Mol. Med. Rep.16(4), 5450–5458 (2017).
- HanahanD. Hallmarks of Cancer: New Dimensions. Cancer Discov.12(1), 31–46 (2022). http://cancerdiscovery.aacrjournals.org/lookup/doi/10.1158/2159-8290.CD-21-1059